ReachMD offentlig
[search 0]
Flere
Download appen!
show episodes
 
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
  continue reading
 
Loading …
show series
 
CME credits: 0.50 Valid until: 23-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-practice-changing-strategies-in-community-care-settings-for-patients-with-cllsll-and-mcl/18098/ Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (…
  continue reading
 
CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-and-when-to-manage-ruxolitinib-failure/26505/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly imp…
  continue reading
 
CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhi…
  continue reading
 
CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-to-use-prognostic-risk-scoring-and-symptom-burden-assessment-to-tailor-myelofibrosis-treatment/26504/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particu…
  continue reading
 
CME credits: 0.50 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-precision-payloads-exploring-adc-directed-therapies-in-her2-mutant-and-overexpressing-lung-cancer/16609/ Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER…
  continue reading
 
CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-thrombocytopenia/26510/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significa…
  continue reading
 
CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-treatment-related-toxicities-with-jak-inhibitor-therapy-in-myelofibrosis/26511/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopen…
  continue reading
 
CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/pacritinib-for-myelofibrosis-across-the-cytopenic-spectrum/26507/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can s…
  continue reading
 
CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/treatment-options-for-ruxolitinib-intolerance-or-resistance-in-myelofibrosis/26506/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic my…
  continue reading
 
CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-transfusion-independence-with-jak-inhibitor-therapy/26509/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, ca…
  continue reading
 
CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-anemia/26508/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly impro…
  continue reading
 
CME credits: 0.50 Valid until: 18-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancements-in-gu-cancers-key-data-from-aua-2024/24417/ Despite treatment advances in genitourinary cancers, most patients will develop relapsed disease. Thus, new treatment approaches are needed, as well as improved methods to identify patients who…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/enhancing-outcomes-in-unresectable-hcc-through-integrated-multidisciplinary-care-models/26337/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations f…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-unmet-needs-in-the-field-of-unresectable-hcc/26329/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable he…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/use-of-ici-combination-regimens-in-patients-with-intermediate-stage-hcc/26333/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/selecting-the-optimal-ici-partner-for-first-line-treatment-of-unresectable-hcc-ctla-4-vs-vegf-inhibitors/26332/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (IC…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-ici-combinations-in-patients-with-unresectable-hcc/26336/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combination…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-supporting-first-line-durvalumabtremelimumab-in-unresectable-hcc/26330/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the tre…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-treatment-options-for-an-unresectable-hcc-patient-who-has-esophageal-varices/26335/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations…
  continue reading
 
CME credits: 1.50 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-by-case-optimizing-dual-immune-checkpoint-inhibitor-combination-therapies-in-advanced-driver-negative-nonsmall-cell-lung-cancer/24418/ Struggling to navigate the latest immunotherapy options for advanced NSCLC? This online CME program delves int…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-supporting-first-line-atezolizumabbevacizumab-in-unresectable-hcc/26331/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the tr…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-first-line-ici-combination-regimens-in-patients-with-unresectable-hcc/26334/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the tr…
  continue reading
 
CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/empowering-treatment-choice-the-essential-role-of-shared-decision-making-in-unresectable-hcc/26338/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinati…
  continue reading
 
CME credits: 1.00 Valid until: 16-11-2024 Claim your CME credit at https://reachmd.com/programs/project-oncology/program-name/26365/ This 1.0-credit activity provides oncology clinicians with practical insights into the importance of biomarker testing in patients diagnosed with metastatic colorectal cancer (mCRC), optimizing biomarker testing proce…
  continue reading
 
CME credits: 1.00 Valid until: 10-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/spinal-muscular-atrophy-optimizing-the-management-of-adults-in-the-era-of-disease-modifying-therapies/26352/ Explore this on-demand webcast for an in-depth expert presentation and case discussion. This educational initiative is designed to help neuro…
  continue reading
 
Loading …

Hurtig referencevejledning